APDM was founded with the objective of creating novel technologies to
- enable the scientific community to conduct quality research in movement science,
- accelerate clinical trials by introducing a new generation of biomarkers and validated endpoints, and
- improve the quality of life of people with movement disorders through precision medicine for neurodegenerative diseases.
APDM, AN ERT COMPANY
ERT, the leader in clinical endpoints data collection, has acquired APDM Wearable Technologies. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.
